Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Ranibizumab
Diclofenac
Cyclosporine A
 
 
Survey

Do you repeat SLT treatment more than twice in the same section of TM?

Yes
50%
No
50%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


April 23, 2014
Retina therapy
Ranibizumab stabilizes vision in patients with RAP
Intravitreal ranibizumab (IVR) stabilizes vision in patients with retinal angiomatous proliferation (RAP), according to researchers from Japan. More...
Post surgery pain
Topical diclofenac offers no extra benefit for post-PRK pain
Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to recent research. More...
Neuroprotection in glaucoma
Neuroprotective effects of cyclosporine A deserve more study
Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers recently reported. More...
Product Profile
ZEISS Cataract Suite markerless
Align toric IOLs and skip the manual marking and data transfer steps with products designed to work together for markerless toric IOL alignment.
Read more
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: